Prevention and Treatment of Early Postoperative Atelectasis Using The MetaNeb System in Patients Underwent Esophagectomy
Status
Conditions
Treatments
Details and patient eligibility
About
The goal of this clinical trial is to evaluate whether the MetaNeb® System can effectively prevent and treat early postoperative atelectasis in adult patients admitted to ICU after esophagectomy for esophageal cancer.
The main question it aims to answer is: can the MetaNeb® system significantly reduce the lung ultrasound score (LUSS) indicating atelectasis on postoperative days 1 and 2? Participants will be randomly assigned to either the standard treatment or MetaNeb group, undergo lung ultrasound and electrical impedance tomography (EIT) assessments on postoperative days 1 and 2, receive at least 4 sessions of MetaNeb therapy on postoperative day 1 if in the intervention group, be monitored for oxygenation indices, ICU stay duration, incidence of mechanical ventilation, need for bronchoscopic intervention, and adverse events like pneumothorax.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age between 18 and 85 years.
- Patients who are scheduled for ICU admission after esophagectomy for esophageal cancer.
Exclusion criteria
- Presence of an artificial airway at the time of ICU admission.
- Planned ICU stay less than 24 hours.
- Patients with contraindications to the use of the MetaNeb® System, or those unable to cooperate due to organic or psychiatric conditions.
Trial design
Primary purpose
Allocation
Interventional model
Masking
178 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Minhui Dong
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal